BioCryst Announces Partnerships for Peramivir for Influenza Outsid...(ough pre-clinical and early development ...),Health

Date:9/15/2009

ough pre-clinical and early development to address the unmet medical needs of patients and physicians. The Company's strategic partnerships with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Limited validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at www.biocryst.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that peramivir may not receive emergency use authorization; that the U.S. government and ex-U.S. governments may choose not to issue a request for peramivir to treat influenza or such requests, if any, may not result in an order or such order, if any, may not be profitable for BioCryst ; that to the extent peramivir is used as a treatment for H1N1 flu (or other strains of flu), there can be no assurance that it will prove effective; that HHS may further condition, reduce or eliminate future funding of the peramivir program; that ongoing peramivir clinical trials or our peramivir program in general may not be successful; that BioCrys
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. BioCryst Executives to Present at Two Investor Conferences
2. BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update
3. BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology
4. BioCryst to Present at the 11th Annual BIO CEO & Investor Conference
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009
6. BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
7. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
8. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
9. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
10. avVaa World Health Care Products, Inc. Announces DRTV Test Results
11. Building Healthier America Announces the High Five Program Addressing Factors Affecting the Energy Levels of Overweight Men